<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01519245</url>
  </required_header>
  <id_info>
    <org_study_id>67452-01</org_study_id>
    <nct_id>NCT01519245</nct_id>
  </id_info>
  <brief_title>Topical Application of Tranexamic Acid to Reduce Post-operative Bleeding in Coronary Artery Bypass Surgery</brief_title>
  <official_title>Topical Application of Tranexamic Acid to Reduce Post-operative Bleeding in Coronary Artery Bypass Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Saskatoon Health Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Saskatchewan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this project is to determine whether the use of tranexamic acid, a clot-promoting
      drug, applied topically over the heart in coronary artery bypass graft surgery (CABG) will
      reduce post operative blood loss. The investigators' hypothesis is that the use of a
      tranexamic acid-containing cardiac bath prior to chest closure will result in a statistically
      significant reduction in blood loss and transfusion requirements in patients who undergo
      CABG.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bleeding is expected during major surgeries. In patients who undergo CABG, the risk for
      bleeding is increased because of the need for intra-operative anticoagulation, or thinning,
      of patient blood. This anticoagulation is necessary to reduce the risk of thrombosis
      potentially precipitated by the cardiopulmonary bypass machine, which pumps blood throughout
      the body while the surgeon operates on the heart.

      Strategies are currently used in the operating room to minimize blood loss and the need for
      allogenic blood transfusion during and after cardiac surgeries. These strategies include the
      use of intravenous antifibrinolytic agents, intra-operative red blood cell salvage devices,
      and topical fibrin sealants. Although the risk of infection from a blood transfusion is very
      small with modern methods of blood screening, the risk of developing a transfusion reaction
      is possible and not predictable. Therefore, it is preferred to avoid administering a blood
      transfusion unless absolutely necessary.

      The use of topical antifibrinolytic agents has been explored to further reduce blood loss in
      cardiac surgery. Several trials have been published in the literature since 1993 evaluating
      the efficacy of various antifibrinolytic medications applied topically, as a cardiac bath,
      prior to chest closure in CABG patients to reduce post-operative blood loss and potential
      need for blood transfusion.

      The applicability of the methodology utilized in these studies, however, is limited in the
      context of the current Canadian practices of cardiac surgery. Considerable differences in the
      perioperative strategies of these trials are seen, in comparison to current North American
      practices of cardiac surgery. These trials also compared use of topically applied
      antifibrinolytic agents, including the lysine analogue tranexamic acid, to a control in the
      absence of intravenous antifibrinolytic agents. The use of intravenous lysine analogues to
      reduce peri-operative bleeding has now become a near-standard of care in CABG patients.

      Currently, the only available antifibrinolytic agent in Canada is the lysine analogue
      tranexamic acid. This drug is widely used administered as an intravenous preparation in
      cardiac surgery because its safety profile and reduction in blood loss and frequency of blood
      transfusion.

      There is presently no published randomized controlled trial evaluating blood loss in CABG
      patients who have received intravenous tranexamic acid, plus topical tranexamic acid or
      placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Volume of Blood Loss From Mediastinal Chest Tubes at Time of Removal (Assuming the Total Volume of Loss is Blood).</measure>
    <time_frame>From ICU admission post-operatively to mediastinal chest tube removal (placebo group = 20.6 hours; trial group = 19.8 hours)</time_frame>
    <description>According to standard practice, research participants were be transferred to the intensive care unit (ICU) for post-operative monitoring. Measurement of chest tube output began immediately on arrival to the ICU. Hourly measurements were recorded. Data collection ended upon chest tube removal, or return to the operating room for exploratory surgery due to massive blood loss. As per ICU protocol, chest tubes were be removed when blood loss was recorded to be less than 200mL after six consecutive hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Units of Packed Red Blood Cells (PRBC) Transfused Following Coronary Artery Bypass Graft Surgery</measure>
    <time_frame>From ICU admission to transfer to the Cardiology Ward (placebo group = 24.4 hours; trial group = 24.7 hours)</time_frame>
    <description>Research participants were to receive a blood transfusion in the Intensive Care Unit (ICU) post-operatively if hemoglobin reached a nadir of 80g/L, or at the discretion of the intensivist or cardiac surgeon according to patient clinical status. Transfusion was quantified based on the number of units of PRBC received. (1 unit = 1 bag of blood, as prepared by Canadian Blood Services). Clinical status of research participants was followed throughout their duration in the ICU only. Participation in this study ended upon transfer out of the ICU, to the Cardiology Ward.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volume of Blood Loss at 6 Hours</measure>
    <time_frame>6 hours following admission to the Intensive Care Unit</time_frame>
    <description>Volume of chest tube loss at 6 hours (assuming the total volume of loss is blood).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Blood Loss After 12 Hours</measure>
    <time_frame>12 hours following admission to the Intensive Care Unit</time_frame>
    <description>Volume of chest tube loss at 12 hours (assuming the total volume of loss is blood).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Trial Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solution containing 2 grams tranexamic acid + normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Solution containing 2 grams (20mL) tranexamic acid + normal saline (50mL), for a total volume of 70mL poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction.</description>
    <arm_group_label>Trial Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>A total volume of 70mL of normal saline poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction. Identical in appearance to the trial drug, and is visually indistinguishable.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criterion:

          -  Patients scheduled for elective or urgent CABG of two to six vessels

        Exclusion Criteria:

        Preoperative:

          -  Hemoglobin of less than 110g/L

          -  Under 18 years of age

          -  Body mass less than 75kg

          -  Presence of an intra-aortic balloon pump

          -  Emergency surgery, requiring operative intervention within 24 hours of consultation to
             the cardiac surgery team

          -  Need for cardiac surgical intervention in addition to planned CABG (with the exception
             of patent foramen ovale closure)

          -  Ejection fraction (EF) of less than 50%, as determined by echocardiogram or
             angiography

          -  Pulmonary hypertension with pulmonary artery pressures greater than 60mmHg (as
             estimated by right ventricular systolic pressure (RVSP))

          -  Presence of infectious endocarditis

          -  Hepatic failure with impaired liver function, including International Normalized Ratio
             (INR) greater than 1.5

          -  Known diagnosed bleeding disorder

          -  History of heparin induced thrombocytopenia and thrombosis (HITT)

          -  Renal failure with pre-operative creatinine greater than 200ml/min or oliguria with
             urine output less than 10ml/hour

          -  Allergy to tranexamic acid

          -  Pregnancy

        Intraoperative:

          -  Discovery of infectious endocarditis

          -  Need for cardiac surgical intervention in addition to planned coronary CABG

          -  Development of allergic reaction to tranexamic acid following intravenous infusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelsey Brose, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan, Department of Medicine, Division of Hematology</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <reference>
    <citation>Abrishami A, Chung F, Wong J. Topical application of antifibrinolytic drugs for on-pump cardiac surgery: a systematic review and meta-analysis. Can J Anaesth. 2009 Mar;56(3):202-12. doi: 10.1007/s12630-008-9038-x. Epub 2009 Feb 12. Review.</citation>
    <PMID>19247741</PMID>
  </reference>
  <reference>
    <citation>Abul-Azm A, Abdullah KM. Effect of topical tranexamic acid in open heart surgery. Eur J Anaesthesiol. 2006 May;23(5):380-4. Epub 2006 Jan 27.</citation>
    <PMID>16438759</PMID>
  </reference>
  <reference>
    <citation>Baric D, Biocina B, Unic D, Sutlic Z, Rudez I, Vrca VB, Brkic K, Ivkovic M. Topical use of antifibrinolytic agents reduces postoperative bleeding: a double-blind, prospective, randomized study. Eur J Cardiothorac Surg. 2007 Mar;31(3):366-71; discussion 371. Epub 2007 Jan 10.</citation>
    <PMID>17218108</PMID>
  </reference>
  <reference>
    <citation>De Bonis M, Cavaliere F, Alessandrini F, Lapenna E, Santarelli F, Moscato U, Schiavello R, Possati GF. Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study. J Thorac Cardiovasc Surg. 2000 Mar;119(3):575-80.</citation>
    <PMID>10694619</PMID>
  </reference>
  <reference>
    <citation>Fawzy H, Elmistekawy E, Bonneau D, Latter D, Errett L. Can local application of Tranexamic acid reduce post-coronary bypass surgery blood loss? A randomized controlled trial. J Cardiothorac Surg. 2009 Jun 18;4:25. doi: 10.1186/1749-8090-4-25.</citation>
    <PMID>19538741</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2012</study_first_submitted>
  <study_first_submitted_qc>January 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2012</study_first_posted>
  <results_first_submitted>December 6, 2012</results_first_submitted>
  <results_first_submitted_qc>May 27, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 2, 2013</results_first_posted>
  <last_update_submitted>May 27, 2013</last_update_submitted>
  <last_update_submitted_qc>May 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>coronary artery bypass grafting</keyword>
  <keyword>tranexamic acid</keyword>
  <keyword>antifibrinolytic</keyword>
  <keyword>administration, topical</keyword>
  <keyword>operative blood salvage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All patients scheduled to undergo elective or urgent CABG at Royal University Hospital between December 1, 2011 and April 30, 2012 were screened for participation. Patients meeting inclusion criteria were approached by a study team member at the time of pre-admission clinic attendance or on the in-patient ward with an invitation to participate.</recruitment_details>
      <pre_assignment_details>Patients meeting inclusion criteria were eligible for study participation. Randomization of consented participants took place by the Clinical Trials Pharmacy on the day of surgery, following confirmation of surgical procedure. The study team could withdraw consented patients prior to randomization and surgery if exclusion criteria were identified.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Trial Drug</title>
          <description>Total 70mL solution containing 2 grams tranexamic acid (20mL) + normal saline (50mL)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Normal saline (70mL)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Pre-pump IV TXA</title>
              <participants_list>
                <participants group_id="P1" count="21">Two patients included in in the final analysis did not receive pre-pump IV TXA.</participants>
                <participants group_id="P2" count="18">All patients meeting inclusion criteria received appropriate dosing, as per protocol.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Post-pump IV TXA</title>
              <participants_list>
                <participants group_id="P1" count="6">A break in protocol, dosing was given in the operating room at the surgeon's preference.</participants>
                <participants group_id="P2" count="2">A break in protocol, dosing was given in the operating room at the surgeon's preference.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Met exclusion criteria, not analysed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Trial Drug</title>
          <description>Total 70mL solution containing 2 grams tranexamic acid (20mL) + normal saline (50mL)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Normal saline (70mL)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" spread="8.7"/>
                    <measurement group_id="B2" value="62" spread="10.4"/>
                    <measurement group_id="B3" value="62" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mass</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92.7" spread="10.5"/>
                    <measurement group_id="B2" value="91.3" spread="13.2"/>
                    <measurement group_id="B3" value="92.2" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.7" spread="0.1"/>
                    <measurement group_id="B2" value="1.7" spread="0.1"/>
                    <measurement group_id="B3" value="1.7" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.1" spread="4.2"/>
                    <measurement group_id="B2" value="31.2" spread="5.1"/>
                    <measurement group_id="B3" value="31.1" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Bypasses</title>
          <description>Mean number of vessels bypassed per patient.</description>
          <units>Number of vessels</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.1" spread="1.0"/>
                    <measurement group_id="B2" value="4.3" spread="1.1"/>
                    <measurement group_id="B3" value="4.2" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-operative Antiplatelet Use</title>
          <description>Participants receiving Aspirin (ASA) or Plavix (any dose) pre-operatively. Divided in to two categories: discontinuation of antiplatelet agents prior to, or at 7 days before surgery; and more than 7 days before surgery.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Off 7 days or less</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Off more than 7 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Angina</title>
          <description>Symptomatic angina in weeks leading up to surgery.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Myocardial Infarction</title>
          <description>Diagnosed myocardial infarction at any time in participant's past history.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stent in situ</title>
          <description>Any history of participant receiving a coronary vascular stent (bare metal or drug eluding).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <description>Diagnosis of Type 1 or 2 diabetes (non-insulin dependent or insulin dependent).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dyslipidemia</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Atrial Fibrillation</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-operative Hemoglobin</title>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147" spread="13"/>
                    <measurement group_id="B2" value="142" spread="14"/>
                    <measurement group_id="B3" value="145" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-operative platelet count</title>
          <units>platelets x 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="242" spread="70"/>
                    <measurement group_id="B2" value="234" spread="62"/>
                    <measurement group_id="B3" value="239" spread="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-operative white blood cell (WBC) count</title>
          <units>WBC x 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.7" spread="1.9"/>
                    <measurement group_id="B2" value="7.9" spread="3.2"/>
                    <measurement group_id="B3" value="7.8" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-operative International Normalized Ratio (INR)</title>
          <description>The ratio of a patient's prothrombin time to a normal (control) sample, raised to the power of the International Sensitivity Index (ISI) value for the analytical system used. The calculated value indicates what a patient's PT ratio would be if it was measured using the primary World Health Organization International Reference reagent. The normal range is 0.8-1.2.</description>
          <units>International Normalized Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.0" spread="0.1"/>
                    <measurement group_id="B2" value="1.0" spread="0.1"/>
                    <measurement group_id="B3" value="1.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-operative Creatinine</title>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84" spread="25"/>
                    <measurement group_id="B2" value="76" spread="18"/>
                    <measurement group_id="B3" value="81" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Volume of Blood Loss From Mediastinal Chest Tubes at Time of Removal (Assuming the Total Volume of Loss is Blood).</title>
        <description>According to standard practice, research participants were be transferred to the intensive care unit (ICU) for post-operative monitoring. Measurement of chest tube output began immediately on arrival to the ICU. Hourly measurements were recorded. Data collection ended upon chest tube removal, or return to the operating room for exploratory surgery due to massive blood loss. As per ICU protocol, chest tubes were be removed when blood loss was recorded to be less than 200mL after six consecutive hours.</description>
        <time_frame>From ICU admission post-operatively to mediastinal chest tube removal (placebo group = 20.6 hours; trial group = 19.8 hours)</time_frame>
        <population>A total of 44 consented participants were randomized. Prior to unblinding, 3 of the randomized participants were withdrawn from the study due to discovery of ineligibility criteria (1 EF &lt;50%, 1 weight &lt;75kg, 1 CABG x 7). Therefore, a total 41 patients were included in final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Trial Drug</title>
            <description>Total 70mL solution containing 2 grams tranexamic acid (20mL) + normal saline (50mL)
Total duration that chest tubes were in-situ before removal = 20 hours (SD 3)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline (70mL)
Total duration that chest tubes were in-situ before removal = 21 hours (SD 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Total Volume of Blood Loss From Mediastinal Chest Tubes at Time of Removal (Assuming the Total Volume of Loss is Blood).</title>
          <description>According to standard practice, research participants were be transferred to the intensive care unit (ICU) for post-operative monitoring. Measurement of chest tube output began immediately on arrival to the ICU. Hourly measurements were recorded. Data collection ended upon chest tube removal, or return to the operating room for exploratory surgery due to massive blood loss. As per ICU protocol, chest tubes were be removed when blood loss was recorded to be less than 200mL after six consecutive hours.</description>
          <population>A total of 44 consented participants were randomized. Prior to unblinding, 3 of the randomized participants were withdrawn from the study due to discovery of ineligibility criteria (1 EF &lt;50%, 1 weight &lt;75kg, 1 CABG x 7). Therefore, a total 41 patients were included in final analysis.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="632" spread="265"/>
                    <measurement group_id="O2" value="789" spread="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Intention to Treat principles of data analysis were applied. The two-sided T-test (95% confidence interval) was used for statistical calculation of primary outcomes. The null hypothesis was that no difference in chest tube losses would be found between the topical tranexamic acid and placebo groups in low-risk cardiac patients undergoing CABG.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0493</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Units of Packed Red Blood Cells (PRBC) Transfused Following Coronary Artery Bypass Graft Surgery</title>
        <description>Research participants were to receive a blood transfusion in the Intensive Care Unit (ICU) post-operatively if hemoglobin reached a nadir of 80g/L, or at the discretion of the intensivist or cardiac surgeon according to patient clinical status. Transfusion was quantified based on the number of units of PRBC received. (1 unit = 1 bag of blood, as prepared by Canadian Blood Services). Clinical status of research participants was followed throughout their duration in the ICU only. Participation in this study ended upon transfer out of the ICU, to the Cardiology Ward.</description>
        <time_frame>From ICU admission to transfer to the Cardiology Ward (placebo group = 24.4 hours; trial group = 24.7 hours)</time_frame>
        <population>None of the research participants received PRBC transfusion postoperatively in the ICU.</population>
        <group_list>
          <group group_id="O1">
            <title>Trial Drug</title>
            <description>Total 70mL solution containing 2 grams tranexamic acid (20mL) + normal saline (50mL)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline (70mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Units of Packed Red Blood Cells (PRBC) Transfused Following Coronary Artery Bypass Graft Surgery</title>
          <description>Research participants were to receive a blood transfusion in the Intensive Care Unit (ICU) post-operatively if hemoglobin reached a nadir of 80g/L, or at the discretion of the intensivist or cardiac surgeon according to patient clinical status. Transfusion was quantified based on the number of units of PRBC received. (1 unit = 1 bag of blood, as prepared by Canadian Blood Services). Clinical status of research participants was followed throughout their duration in the ICU only. Participation in this study ended upon transfer out of the ICU, to the Cardiology Ward.</description>
          <population>None of the research participants received PRBC transfusion postoperatively in the ICU.</population>
          <units>Unit(s) of PRBC</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Blood Loss at 6 Hours</title>
        <description>Volume of chest tube loss at 6 hours (assuming the total volume of loss is blood).</description>
        <time_frame>6 hours following admission to the Intensive Care Unit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trial Drug</title>
            <description>Total 70mL solution containing 2 grams tranexamic acid (20mL) + normal saline (50mL)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline (70mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Blood Loss at 6 Hours</title>
          <description>Volume of chest tube loss at 6 hours (assuming the total volume of loss is blood).</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342" spread="191"/>
                    <measurement group_id="O2" value="417" spread="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Intention to Treat principles of data analysis were applied. The two-sided T-test (95% confidence interval) was used for statistical calculation of secondary outcomes. The null hypothesis was that no difference in chest tube losses would be found between the topical tranexamic acid and placebo groups in low-risk cardiac patients undergoing CABG.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1876</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Blood Loss After 12 Hours</title>
        <description>Volume of chest tube loss at 12 hours (assuming the total volume of loss is blood).</description>
        <time_frame>12 hours following admission to the Intensive Care Unit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Trial Drug</title>
            <description>Total 70mL solution containing 2 grams tranexamic acid (20mL) + normal saline (50mL)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Normal saline (70mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Blood Loss After 12 Hours</title>
          <description>Volume of chest tube loss at 12 hours (assuming the total volume of loss is blood).</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="464" spread="222"/>
                    <measurement group_id="O2" value="570" spread="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Intention to Treat principles of data analysis were applied. The two-sided T-test (95% confidence interval) was used for statistical calculation of secondary outcomes. The null hypothesis was that no difference in chest tube losses would be found between the topical tranexamic acid and placebo groups in low-risk cardiac patients undergoing CABG.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0930</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout study period duration, and until last enrolled patient was transferred out of the ICU (December 2, 2011-May 3, 2012).</time_frame>
      <desc>Development of clinically significant vascular or material thrombosis were considered adverse events (cerebrovascular thrombosis, myocardial infarction, deep venous thrombosis, pulmonary embolism or obstructive clot within the mediastinal chest tubes). No serious or other adverse events were observed throughout the duration of the study period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Trial Drug</title>
          <description>Total 70mL solution containing 2 grams tranexamic acid (20mL) + normal saline (50mL)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Normal saline (70mL)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size
Low-risk CABG patients enrolled only
Break in protocol, with pre-pump TXA not given to 2 participants, and post-pump TXA given to 8 participants
Short study period, with no long-term follow-up data</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Kelsey Brose, Primary Investigator</name_or_title>
      <organization>University of Saskatchewan</organization>
      <phone>306-655-1483</phone>
      <email>kelsey.brose@saskcancer.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

